The city is the second in the UK to join the Novo Nordisk led partnership programme
News
Amgen unveils five-year survival data for Blincyto
Early achievement of complete molecular remission with Blincyto is linked with prolonged survival, researchers note
AZ’ Calquence shows PFS benefit in CLL patients
A new filing for the drug as a treatment for relapsed or refractory chronic lymphocytic leukaemia is expected later this year
GSK, Uni of California pair up to advance genomic research
The LGR will receive up to $67 million in funding over a five-year period.
Outdated technology systems still ‘limiting’ UK patient care
Over a third (36%) of respondents’ staff have asked for faster digital technology systems.
Rituxan hits endpoints in late-stage skin disease trial
The drug demonstrated superiority to current standard-of-care to CellCept.
ABPI publishes new guidelines on pharma working with patients
The sourcebook covers six topics, which were identified as areas where further guidance would be of assistance.
Gilead, AbCellera team up against infectious diseases
AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties.
Pixuvri approved for use in EU
The drug has been granted the conversion of the conditional approval into standard marketing authorisation as a single agent.
AZ’ Farxiga shows 47% reduction in kidney function decline
The SGLT2 inhibitor was evaluated in 17,160 patients with type II diabetes.
Invokana hits endpoints in cardiovascular trial
A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
Strive for success in the 2019 Medical & Scientific Excellence Awards
This competition aims to honour those with exceptional talent within the medical and scientific industry, by offering a platform for candidates to share best practice and prove they’ve got the skills to be successful.
Boehringer, Lilly present positive Trajenta results at ADA
The study is the only active-comparator cardiovascular outcome trial for a DPP-4 inhibitor.
Cosentyx shows efficacy in key manifestations of psoriatic arthritis
The data will be presented at the Annual European Congress of Rheumatology (EULAR) on 12-15 June in Madrid, Spain.
